Tactile Systems Technology Inc
NASDAQ:TCMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (11.5), the stock would be worth $21.78 (15% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 13.4 | $25.52 |
0%
|
| 3-Year Average | 11.5 | $21.78 |
-15%
|
| 5-Year Average | 11.4 | $21.73 |
-15%
|
| Industry Average | 12.9 | $24.45 |
-4%
|
| Country Average | 14.4 | $27.24 |
+7%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
$554.7m
|
/ |
Jan 2026
$35.9m
|
= |
|
|
$554.7m
|
/ |
Dec 2026
$48.8m
|
= |
|
|
$554.7m
|
/ |
Dec 2027
$59.3m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Tactile Systems Technology Inc
NASDAQ:TCMD
|
572.6m USD | 13.4 | 30 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
166.7B USD | 14.5 | 26.6 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
165.3B USD | 43.9 | 57.9 | |
| US |
|
Stryker Corp
NYSE:SYK
|
131.3B USD | 20.4 | 39.9 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
109.1B USD | 13.1 | 23.6 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
90.4B USD | 18.6 | 31.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
43.2B EUR | 11.4 | 20.5 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.3B USD | 24 | 44.1 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
46.5B USD | 31 | 43.9 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
45.2B USD | 10.1 | 25.7 | |
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
33.8B USD | 11.6 | 16.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Tactile Systems Technology Inc
Glance View
Tactile Systems Technology, Inc. is a medical technology company. The company is headquartered in Minneapolis, Minnesota and currently employs 988 full-time employees. The company went IPO on 2016-07-28. Its therapeutic focus is vascular disease, for treating lymphedema and chronic venous insufficiency. The company is a manufacturer and distributor of the Flexitouch and Entre systems, medical devices that help control symptoms of lymphedema, a chronic and progressive medical condition. Its at-home Flexitouch system provides automated, at-home lymphatic drainage therapy. Its Flexitouch Plus system is an automated, programmable, pneumatic compression device (APCD), designed for the treatment of lymphedema in the home setting. Its Entre system is a pneumatic compression device used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company possesses a platform to deliver at-home healthcare solutions directly to patients throughout the United States.
